Rongchang Biotechnology: Application for Clinical Trial of Antibody-Drug Conjugate RC278 Accepted for Review

Rongchang Bio announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration for the clinical trial application for the injection of the new antibody-drug conjugate RC278. RC278 is a first-in-class/best-in-class ADC molecule independently developed by Rongchang Bio. This molecule can specifically recognize a new tumor target and has an innovative linker-toxin system. In preclinical studies, it has shown broad-spectrum anti-tumor activity, good safety, and pharmacokinetic characteristics, bringing new treatment options for late-stage solid tumor patients.